Mosaic Immuno Engineering Inc. CPMV
We take great care to ensure that the data presented and summarized in this overview for Mosaic ImmunoEngineering Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CPMV
Top Purchases
Top Sells
About CPMV
Mosaic ImmunoEngineering Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. It offers MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in mice, dogs, and humans. The company was founded in 2020 and is based in Novato, California.
Insider Transactions at CPMV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 29
2021
|
Robert L Garnick Director |
BUY
Conversion of derivative security
|
Direct |
356,794
+50.0%
|
-
|
|
Jan 29
2021
|
Steven W King President and CEO |
BUY
Conversion of derivative security
|
Direct |
1,641,252
+50.0%
|
-
|
|
Jan 29
2021
|
Paul J Lytle EVP, Chief Financial Officer |
BUY
Conversion of derivative security
|
Direct |
1,641,252
+50.0%
|
-
|
|
Jan 29
2021
|
Nicole Franziska Steinmetz Director |
BUY
Conversion of derivative security
|
Indirect |
570,870
+50.0%
|
-
|
|
Jan 29
2021
|
Nicole Franziska Steinmetz Director |
BUY
Conversion of derivative security
|
Direct |
1,641,252
+50.0%
|
-
|